DOCSLIB.ORG

Seventh Congress of the International Bioiron Society (IBIS)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Seventh Congress of the International Bioiron Society (IBIS) Seventh Congress of the International BioIron Society (IBIS) Biennial World Meeting (BioIron 2017) May 7 – 11, 2017 UCLA Meyer & Renee Luskin Conference Center | Los Angeles, USA Featuring Special Events: Introductory Course – May 7, 2017 “Essentials of BioIron for Clinicians and Scientists” “Meet the Expert” Sessions for Trainees May 10 – 11, 2017 INTERNATIONAL BIOIRON SOCIETY PROGRAM BOOK Acknowledgments IBIS This conference has received support from the NIH NCATS UCLA CTSI Grant Number UL1TR0001881. This conference has received support from the NIH/NIDDK R-13 Grant. This conference has received support from the NIXHNHLBI-R-13 Grant. Seventh Congress of the International BioIron Society Page 2 Table of Contents IBIS Seventh Congress of the Internationl BioIron Society (IBIS) Biennial World Meeting (BioIron 2017) May 7 - 11, 2017 UCLA Meyer & Renee Luskin Conference Center | Los Angeles, USA Welcome Message ..............................................................................................................................Page 4 Board of Directors ................................................................................................................................Page 5 General Meeting Information ...............................................................................................................Page 6 Special Events .....................................................................................................................................Page 8 Local Activities .....................................................................................................................................Page 9 Acknowledgments .............................................................................................................................Page 10 Program Schedule .............................................................................................................................Page 11 Keynote Speaker ...............................................................................................................................Page 51 Abstracts ............................................................................................................................................Page 52 Featured Podium/Poster Abstracts .......................................................................................Page 52 Podium Abstracts ..................................................................................................................Page 61 Poster Abstracts .................................................................................................................Page 116 Late-Breaking Abstracts .....................................................................................................Page 325 Alphabetical Index of Presenters .....................................................................................................Page 378 Meeting Title Page 3 Welcome IBIS Dear Friends and Colleagues, Welcome to the Seventh Congress of the International BioIron Society (IBIS) being held at the University of California, Los Angeles. In keeping with the character of the organization, the BioIron 2017 Meeting is held is a different continent every biennial cycle, returning to North America for the first time since Vancouver in 2011. This continues to be an exciting time in the field of iron research. Molecular discoveries over the past two decades have led to a rapid expansion in the number of potential biomarkers and targets for treatment for iron-related diseases. Indeed many of these discoveries hold promise to make major contributions to the well-being of a large number of people suffering from iron-related disorders across the globe. The program planned by the IBIS Board and Local Organizing Committee reflects this broadening character of the most compelling questions in iron research. This year, we are including two celebratory sessions: The 30-year anniversary of the discovery of the iron responsive elements, which laid the foundation for understanding cellular iron regulation, and the 50-year anniversary of therapeutic iron chelation which improved and prolonged the lives of so many patients with iron overload. These sessions feature outstanding presentations highlighting not only why these events were so seminal, but where they provide opportunities for future application. We especially welcome participants new to iron research. In keeping with past several meetings, the first day will be an introductory course to provide a helpful framework for critical understanding of the research to be presented during the main meeting. The course is intended for an audience of diverse backgrounds, and provides ample time for questions. We strongly encourage trainees in the audience to contribute to this discussion. In addition to scheduled opportunities for trainees to meet-the-experts, we have added two special “Interviews with the Masters” to share the wisdom provided by long and highly successful careers in iron research. The name of our organization serves as an acknowledgement that science is a social as well as investigative process. We hope you will take time to enjoy the wonderful setting the Southern California provides. We will have a communal outing to the beautiful and unique Getty Museum on Tuesday afternoon, and a fun, entertaining Gala and Awards Dinner to close the meeting. We wish to express our gratitude to all our sponsors for their generous contributions to this event. It is impossible to hold a meeting of this scope and caliber without the contributions from the biotechnology and pharmaceutical companies that ultimately translate scientific discovery into practical applications. We equally appreciate the support from National Institutes of Health in providing travel bursaries for trainees to attend this meeting. We would also like to express our thanks for the highly professional organizational work performed by Heather Swanson and her staff at W.J. Weiser. Most of all, we are grateful to each of you for contributing your time and effort to participate in this global sharing of ideas and discoveries. Thank you again for being part of BioIron 2017. Robert E Fleming, MD, IBIS President Elizabeta Nemeth, PhD and Tomas Ganz, MD, PhD, Co-Chairs of the Local Organizing Committee Ioav Cabantchik PhD, IBIS President-Elect Seventh Congress of the International BioIron Society Page 4 Board of Directors IBIS OFFICERS President Stefano Rivella, PhD Robert E. Fleming, MD Philadelphia, PA, USA St. Louis, MO, USA Laura Silvestri, PhD President-Elect Milan, Italy Ioav Cabantchik, MD, PhD Jerusalem, Israel Program Committee Robert E. Fleming, MD Secretary St. Louis, MO, USA Helene Coppin, PhD Toulouse Cedex, France Tomas Ganz, MD, PhD Los Angeles, CA, USA Treasurer Domenico Girelli, MD, PhD Elizabeta Nemeth, PhD Verona, Italy Los Angeles, CA, USA Past President Local Organizing Committee Greg Anderson, PhD Tomas Ganz, MD, PhD Brisbane, Australia Los Angeles, CA, USA Board Of Directors Elizabeta Nemeth, PhD Director Los Angeles, CA, USA Robert W. Evans, BA, PhD Uxbridge Middlesex, United Kingdom Headquarter Office WJ Weiser & Associates, Inc. Yelena Ginzburg, MD 1100 E. Woodfield Road, Suite 350 New York, NY, USA Schaumburg, IL 60173 Mitchell Knutson, PhD Executive Director Gainesville, FL, USA Heather Swanson Schaumburg, IL Elizabeta Nemeth, PhD Los Angeles, CA, USA ABSTRACT REVIEWERS Hossein Ardehali, MD, PhD Sonia Levi, PhD Paulo Arosio, PhD Sijin Liu, PhD Ioav Cabantchik, MD, PhD Bryan Mackenzie, PhD Clara Camaschella, MD Esther Meyron-Holtz, PhD Nica Cappellini, MD Elizabeta Nemeth, PhD Hal Drakesmith, PhD Guangjun Nie, PhD Caroline Enns, PhD Kostas Pantopoulos, PhD Mark D. Fleming, MD, DPhil Sant-Rayn Pasricha, MBBS, MPH, PhD Robert E. Fleming, MD John B. Porter, MA, MD, FRCP DRCPath Lucia De Franceschi, MD Grant Ramm, PhD Tomas Ganz, MD, PhD Marie-Paule Roth, MD, PhD Iqbal Hamza, PhD Tracey Rouault, MD Zoubida Karim, PhD Yatrik Shah, PhD Mitchell Knutson, PhD Laura Silvestri, PhD Jan Krijt, PhD V. Nathan Subramaniam, PhD Samira Lakhal-Littleton, PhD Dorine Swinkels, PhD Seventh Congress of the International BioIron Society Page 5 General Meeting Information IBIS Dates of the Conference May 7 – 11, 2017 On Sunday, May 7, 2017, registration will open at 9:00 and the Welcome Reception will begin at 18:30. The BioIron 2017 Meeting will begin with the Opening Ceremony on Monday, May 8, 2017 at 8:00 and will conclude on Thursday, May 11, 2017 at 19:00 with the Gala Dinner and Award Ceremony. Venue Meyer & Renee Luskin Convention Center 425 Westwood Plaza Los Angeles, California, 90095 (855) 522-8252 luskinconferencecenter.ucla.edu Language The official language of the BioIron 2017 Conference will be English. Weather Los Angeles averages a daily maximum temperature for May that's between 72 and 77 degrees Fahrenheit (22 to 25 degrees Celsius). The minimum temperature usually falls between 55 and 59 °F (13 to 15 °C). This time of year may also garner some rain, so waterproof wear is recommended. Money The official currency of Los Angeles, California, USA is the United States Dollar (USD). Notes: $100, $50, $20, $10, $5, $1 Coinage: quarter (25 cents), dime (10 cents), nickel (5 cents), penny (1 cent) Cards: Access, MasterCard, American Express, Diners Club, VISA are widely accepted in shops, restaurants, etc. Retailers now have the option to charge more for goods and services bought by credit card, although they are obliged to display a clear indication that
Load more

Recommended publications
  • (UPCR) Levels in Diabetic Nephropathy Patients
    Journal of Personalized Medicine Article Gender Differences in Genetic Associations of RAB38 with Urinary Protein-to-Creatinine Ratio (UPCR) Levels in Diabetic Nephropathy Patients 1, 2,3,4, 1 1 Zhi-Lei Yu y, Chung-Shun Wong y , Yi Ting Lai , Wan-Hsuan Chou , Imaniar Noor Faridah 1,5, Chih-Chin Kao 6,7 , Yuh-Feng Lin 2,7,8,* and Wei-Chiao Chang 1,9,10,11,* 1 Department of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei 110301, Taiwan; [email protected] (Z.-L.Y.); [email protected] (Y.T.L.); [email protected] (W.-H.C.); [email protected] (I.N.F.) 2 Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110301, Taiwan; [email protected] 3 Department of Emergency Medicine, Taipei Medical University-Shuang Ho Hospital, New Taipei City 235041, Taiwan 4 Department of Emergency Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan 5 Faculty of Pharmacy, Ahmad Dahlan University, Yogyakarta 55164, Indonesia 6 Division of Nephrology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei 110301, Taiwan; [email protected] 7 Division of Nephrology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110301, Taiwan 8 Division of Nephrology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235041, Taiwan 9 Master Program for Clinical Pharmacogenomics and Pharmacoproteomics, School of Pharmacy, Taipei Medical University, Taipei 110301, Taiwan 10 Integrative Research Center for Critical Care, Wan Fang Hospital, Taipei Medical University, Taipei 110301, Taiwan 11 Department of Medical Research, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235041, Taiwan * Correspondence: [email protected] (Y.-F.L.); [email protected] (W.-C.C.) Z.-L.Y.
    [Show full text]
  • Diagnostic Accuracy of Spot Urine Protein-To-Creatinine Ratio For
    O RIGINAL ARTICLE Diagnostic accuracy of spot urine protein-to- creatinine ratio for proteinuria and its association with adverse pregnancy outcomes in Chinese pregnant patients with pre-eclampsia HC Cheung *, KY Leung, CH Choi ABSTRACT diagnosing proteinuria in Chinese pregnant patients (33 mg/mmol) was similar to that stated in the International guidelines have Introduction: international literature (30 mg/mmol). A cut-off of endorsed spot urine protein-to-creatinine ratio of 20 mg/mmol provided a 100% sensitivity, and 52 >30 mg protein/mmol creatinine as an alternative mg/mmol provided a 100% specificity. There was to a 24-hour urine sample to represent significant no significant difference in spot urine protein-to- proteinuria. This study aimed to determine the creatinine ratio between cases with and without accuracy of spot urine protein-to-creatinine ratio adverse pregnancy outcome. in predicting significant proteinuria and adverse pregnancy outcome. Conclusions: Spot urine protein-to-creatinine ratio had a positive and significant correlation with 24-hour This case series was conducted in a Methods: urine results in Chinese pre-eclamptic women when regional obstetric unit in Hong Kong. A total of the ratio was <200 mg/mmol. Nonetheless, this ratio 120 Chinese pregnant patients with pre-eclampsia was not predictive of adverse pregnancy outcome. delivered at Queen Elizabeth Hospital from January 2011 to December 2013 were included. Relationship of spot urine protein-to-creatinine ratio and 24-hour Hong Kong Med J 2016;22:249–55 proteinuria; accuracy of the ratio against 24-hour DOI: 10.12809/hkmj154659 urine protein at different cut-offs; and relationship 1 HC Cheung *, MB, BS, MRCOG of such ratio and adverse pregnancy outcome were 1 KY Leung, FRCOG, FHKAM (Obstetrics and Gynaecology) studied.
    [Show full text]
  • An Unusual Case of Acute Kidney Injury with Edematous Kidneys and Venous Micro Thrombi: a Case Report
    Hijazi F, et al., J Nephrol Renal Ther 2019, 5: 023 DOI: 10.24966/NRT-7313/100023 HSOA Journal of Nephrology & Renal Therapy Case Report countries, AKI is a disease of the young [8] and children [9], in whom An Unusual Case of Acute volume-responsive “prerenal” mechanisms are common [10]. We present a case of a young adult presenting with unexplained AKI. Kidney Injury with Edematous Case History Kidneys and Venous Micro A 20-year-old man with non-significant past medical history who presented to the emergency room with a 2 day-history of low back Thrombi: A Case Report and bilateral flank pain. He also had mild nausea and feverishness. Fadi Hijazi, Nizar Attallah, Rakesh Madhyastha* The patient also reported thirst and polyuria. He did not have edema, rashes, or arthralgia. No respiratory symptoms were reported. He took Department of Nephrology, Medical Subspecialties Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE 10 tablets of acetaminophen and 2 tablets of ibuprofen over those 2 days. He did not have any alcohol or illicit drugs use. Abstract Vital signs were normal. Physical examination was positive for mild costovertebral angle tenderness on both sides. Otherwise, the This case report describes a young patient with Acute Kidney rest of the physical exam was unremarkable. He had no skin rash. Injury (AKI) stage 3, low grade micro-hematuria (3-5 dysmorphic red blood cells in each high power field [RBC/HPF]), low grade pro- Initial laboratory testing revealed a serum creatinine of 341 umol/L teinuria (Urine Protein To Creatinine (UPCR) of around 1 gm/gm), (3.8 mg/dl), and urinalysis showed proteinuria (2+), and 0-3 and 3-5 edematous kidneys on ultrasound, and unusual histologic finding on kidney biopsy.
    [Show full text]
  • Università Degli Studi Di Milano
    UNIVERSITÀ DEGLI STUDI DI MILANO SCUOLA DI DOTTORATO IN MEDICINA MOLECOLARE CICLO XXVIII Anno Accademico 2014/2015 TESI DI DOTTORATO DI RICERCA MED09 STUDIES OF HEME-REGULATED eIF2α KINASE STRESS SIGNALING ON MATURATION OF MACROPHAGES AND ERYTHROBLASTIC ISLAND FORMATION IN IRON RESTRICTIVE ERYTHROPOIESIS Dottorando : Elena PALTRINIERI Matricola N° R10203 TUTORE : Chiar.ma Prof.ssa Maria Domenica CAPPELLINI CO-TUTORE: Prof.ssa Jane-Jane CHEN DIRETTORE DEL DOTTORATO: Chiar.mo Prof. Mario CLERICI ABSTRACT Iron is the most important metal for the human body. Different states of iron deficiency have long existed and remain very common in today’s population. The vast majority of cases of iron deficiency are acquired as a result from blood loss. Any condition in which dietary iron intake does not meet the body’s demands will result in iron deficiency. Iron and heme are both fundamental in hemoglobin synthesis and erythroid cell differentiation. In addition to act as a prosthetic group for hemoglobin, heme regulates the transcription of globin genes and controls the translational activity in erythroid precursors through modulation of the kinase activity of the eIF2α kinase HRI which is regulated by heme. HRI, the heme-regulated inhibitor of translation, was first discovered in reticulocytes under the conditions of iron and heme deficiencies. During heme deficiency conditions, in the erythroid precursors protein synthesis is inhibited by phosphorylation of the α-subunit of the eukaryotic initiation factor 2 (eIF2α) as the result of the activation of HRI. The role of HRI is to control that the amount of globin chains synthesized are not in excess of what can be utilized for hemoglobin tetramers depending of heme available.
    [Show full text]
  • Proteinuria and Hematuria
    Proteinuria and Hematuria Proteinuria (including Albuminuria) Qualitative Testing (dye-impregnated paper strip- “dipstick”)- 1-4+ Quantitative Testing > Urine protein to creatinine ratio (UPCR) (gm/gm) in a “spot” urine sample or a timed collection > Urine albumin to creatinine ratio (UACR) (mg/mg) in a “spot” urine or a timed collection > Urine albumin concentration (mg/dL) (UAC) > Urine albumin excretion rate (mg/d or μg/min (UAER) in timed urinary collection > Urine protein excretion rate (UPER) in a timed urinary collection-usually 24 hours (UACR or UAC preferred) Proteinuria and the Nephrotic Syndrome: Definitions Proteinuria: >Overt- Urinary excretion of >300mg total protein/d or a UPCR of >200mg/gm > Covert- (microalbuminuria) UAER of 30- 300mg albumin/d (20-200μg/min or a UACR of 17-250mg/gm (M) or 25-355mg/gm (F) Nephrotic Syndrome: > Urinary excretion of >3.5gm total protein/d or a UPCR of >3.0gm/gm (Adult) + Hypoalbuminemia (Edema and Hyperlipidemia are variable) Proteinuria: Evaluation Spot morning second voided urine samples are best– UAC or UACR or UPCR Dipstick testing is only semi-quantitative and is influenced by urine concentration (Specific Gravity or Osmolality) Dipstick tests are relatively insensitive for globulins and light-chains False positive Dipsticks with alkaline urine and after contrast agent or cephalosporins Myoglobin and Hemoglobin can give a + test Proteinuria: Evaluation Dipsticks: Negative- <10mg/dL Trace - 10mg/dL 1+- 30mg/dL 2+- 100mg/dL 3+- 300mg/dL 4+- >1000mg/dL Proteinuria: Evaluation
    [Show full text]
  • General Pathology
    Jordan University of Science and Technology Faculty of Medicine 2018-2019 COURSE TITLE : GENERAL PATHOLOGY. COURSE CODE : MED 231. CREDIT HOURS : 3 CREDIT HOURS SEQUENCE : YEAR 2, FIRST SEMESTER COURSE COORDINATOR: Dr. Alia AlMuhtaseb; Dr. Mohammad Orjani CONTACT: [email protected]; [email protected] Course Description: This course deals with the investigation of those pathological mechanisms common to all tissue-cell pathology. Attention is paid to the processes of cellular adaptation, inflammation, repair, immunology, cellular accumulation, and neoplasia. Lecture will attempt first to familiarize the student with our basic layers of defense. Next those vocabulary terms and concepts relevant to the disease process will be introduced. The terminology employed is both medical and chiropractic. Processes and concepts will be developed with the aid of Data show. An interactive format is employed in which the instructor poses questions to enable the student to self-test their knowledge prior to exams and develop skills in communicating these basic pathological concepts to others. During the course and whenever relevant the students are exposed to clinical problems to emphasize the explanations of symptoms, signs, investigations and forms of treatments. Practical sessions are planned to give students the opportunity to expose their knowledge for discussion and confirm concepts learned in lectures. Small group discussions of clinical cases are planned at the end of the course were students are divided into small groups and with the help of an instructor they analyze and discuss the problem. The course will be given through 28 lectures, 7 practical (laboratory) sessions, and one small group discussion activity over 15 weeks and for one whole semester.
    [Show full text]
  • 1 Pathology Week 1 – Cellular Adaptation, Injury and Death
    Pathology week 1 – Cellular adaptation, injury and death Cellular responses to injury Cellular Responses to Injury Nature and Severity of Injurious Stimulus Cellular Response Altered physiologic stimuli: Cellular adaptations: • ↑demand, ↑ trophic stimulation (e.g. growth factors, hormones) • Hyperplasia, hypertrophy • ↓ nutrients, stimulation • Atrophy • Chronic irritation (chemical or physical) • Metaplasia Reduced oxygen supply; chemical injury; microbial infection Cell injury: • Acute and self-limited • Acute reversible injury • Progessive and severe (including DNA damage) • Irreversible injury → cell death Necrosis Apoptosis • Mild chronic injury • Subcellular alterations in organelles Metabolic alterations, genetic or acquired Intracell accumulations; calcifications Prolonged life span with cumulative sublethal injury Cellular aging Hyperplasia - response to increased demand and external stimulation - ↑ number cells - ↑ volume of organ - often occurs with hypertrophy - occurs if cells able to synthesize DNA – mitotic division - physiologic or pathologic Physiological hyperplasia A) hormonal – ↑ functional capacity tissue when needed (breast in puberty, uterus in pregnancy) B) compensatory - ↑ tissue mass after damage/resection (post-nephrectomy) Mechanisms: - ↑ local production growth factors or activation intracellular signaling pathways o both → production transcription factors that turn on cellular genes incl those encoding growth factors, receptors for GFs, cell cycle regulators →→ cellular proli feration - in hormonal hyperplasia
    [Show full text]
  • Cellular Adaptation
    Cellular Adaptation Dr. Adeboye OO (MBBS, Cert. LMIH, FMCPath) Dept of Anatomic Pathology Bowen University Cellular adaptation • Cell death is not the only consequence of cellular injury or stress • Cells can respond to excessive physiologic or pathologic stimuli by undergoing both functional and morphologic change in which a new steady state is achieved that preserves the viability of the cell(Adaptation) . • The adaptive response include- • Adaptation of growth and differentiation • Intracellular accumulation • Pathologic calcification • Hyaline change • Cellular aging Adaptation of growth and differentiation • Adaptations are reversible changes in the size, number,phenotype, metabolic activity, or functions of cells in response to changes in their environment. Such adaptations may take several distinct forms : • 1. hyperplasia • 2. hypertrophy • 3. atrophy • 4. metaplasia hypertrophy • Increase in the size of cells that result in the increase in size of the affected organ. • No new cells just larger cells • May coexist with hyperplasia in cells capable of division( eg epithelial, hematopoesis etc), in non dividing cells (eg the nerve ,cardiac and skeletal muscle) increase tissue mass is due to hypertrophy • Can be physiologic or pathologic Physiologic hypertrophy • Caused by- (a) increased functional demand eg hypertrophy of striated muscle in muscle builder.(b) stimulation by hormones or growth factors eg physiologic hypertrophy of the uterus during pregnancy Hypertrophy of uterus during pregnancy Micrograph showing smooth muscle
    [Show full text]
  • Tissue Engineering Strategies to Improve Tendon Healing and Insertion Site Integration
    Tissue Engineering Strategies to Improve Tendon Healing and Insertion Site Integration A dissertation submitted to the Division of Research and Advanced Studies of the University of Cincinnati in partial fulfillment of the of the requirements for the degree of DOCTOR OF PHILOSOPHY (Ph.D.) in the Department of Biomedical Engineering of the College of Engineering and Applied Science 2011 by Kirsten Rose Carol Kinneberg B.S., University of Minnesota, Twin Cities, MN, 2006 Committee Chair: Jason T. Shearn Abstract Tendon and ligament tears and ruptures remain common and significant musculoskeletal injuries. Repairing these injuries continues to be a prominent challenge in orthopaedics and sports medicine. Despite advances in surgical techniques and procedures, traditional repair techniques maintain a high incidence of re-rupture. This has led some researchers to consider using tissue engineered constructs (TECs). Previous studies in our laboratory have demonstrated that TEC stiffness at the time of surgery is positively correlated with repair tissue stiffness 12 weeks post-surgery. This correlation provided the rationale for implanting a soft tissue patellar tendon autograft (PTA) to repair a central-third defect in the rabbit patellar tendon (PT). The PTA was significantly stiffer than previous TECs and matched the stiffness of the normal central-third PT. Accordingly, we expected a significant improvement in repair tissue biomechanics relative to both natural healing (NH) and TEC repair. At 12 weeks, treatment with PTA improved repair tissue stiffness relative to NH. However, PTA and NH tissues did not differ in maximum force, modulus or maximum stress. Additionally, neither repair group regenerated normal zonal insertion sites.
    [Show full text]
  • Clinical Pharmacy and Clinical Trials Eur J Hosp Pharm: First Published As 10.1136/Ejhpharm-2013-000276.585 on 12 March 2013
    Clinical pharmacy and clinical trials Eur J Hosp Pharm: first published as 10.1136/ejhpharm-2013-000276.585 on 12 March 2013. Downloaded from Conclusions CPC-128 START SMART THEN FOCUS – a Survey oF ANTIMICROBIAL STEWARDSHIP GUIDELINES ●● It showed better clinical outcomes in the gemcitabine plus nab-paclitaxel group in PFS. IMPLEMENTATION IN ENGLAND ●● The nab-paclitaxel can be an effective second-line chemo- doi:10.1136/ejhpharm-2013-000276.585 therapy in gemcitabine resistant patients. 1P Howard, 2J Cooke, 3C Fry, 4C McNulty, 5H Khoda, 3S Wellstead, 6J Stockley, No conflict of interest. 7H Loveday, 5L Brown. 1Leeds Teaching Hospitals NHS Trust, Pharmacy, Leeds, UK; 2University of Manchester, Pharmacy, Manchester, UK; 3Department of Health, Infectious CPC-127 SEVERAL TYPES OF PROTEINURIA AND ASSOCIATED Diseases and Blood Policy, London, UK; 4Health Protection Agency, Primary Care Unit, FACTORS AMONG HIV-INFECTED ADULTS IN THE Gloucester, UK; 5Health Protection Agency, HCAI and AMR Programme Team, London, HAART ERA UK; 6Worcester Acute Hospitals NHS Trust, Microbiology, Worcester, UK; 7University of West London, College of Nursing Midwifery and Healthcare, London, UK doi:10.1136/ejhpharm-2013-000276.584 1E Guiller, 2C Psomas, 3M Chaton, 4A Cournil, 2J Reynes. 1University Hospital of Background Start Smart then Focus Antimicrobial Stewardship Montpellier, Pharmacy, Montpellier Cedex 5, France; 2University Hospital of Montpellier, (AMS) guidance for England was launched in November 2011 on Department of Infectious Diseases, Montpellier Cedex 5, France; 3University Hospital European Antimicrobial Awareness Day. of Montpellier, Biochemistry, Montpellier Cedex 5, France; 4University Hospital of Purpose To identify the extent of guideline implementation, Montpellier, IRD Inst Res Devt, Montpellier Cedex 5, France whether the guidelines had improved AMS, and to collect examples of good practise.
    [Show full text]
  • Cellular Adaptation
    ALTERATIONS IN CELLULAR AND TISSUE FUNCTION Lois E. Brenneman, MSN, APN, CELLULAR ADAPTATION Atrophy - decrease or shrinkage in cell size - Can (if sufficient numbers) result in shrinkage of entire organ Example: muscular atrophy after cast is removed Example: sports steroid abuse causes atrophy of penis - Physiologic atrophy - normal process Example: atrophy of thymus during childhood - Pathologic atrophy - disease process Example: Addison’s disease -> atrophy adrenal glands - Disuse Atrophy Example: Prolonged bed rest causes muscle atrophy Example: Casting limb causes atrophy Atrophic cells have fewer mitochondria and myofilaments Autophagic vacuoles occurs with malnutrition Lipofuscin - yellow-brown age pigment (may resist destruction) - Persists as membrane-bound residue bodies - Accumulates w age: liver, myocardial and atrophic cells - Results in “age spots” to skin “Age spots” Lipofuscin accumulation to skin © 2004 Lois E. Brenneman, MSN, CS, ANP, FNP all rights reserved - www.npceu.com 1 Hypertrophy - increase in cell size (vs cell number with hyperplasia) Results in increased size of organ Cardiac and kidney esp prone to hypertrophy Increased size -> increased cellular protein and not increased fluid Physiologic hypertrophy - normal process Example: muscle increase with exercise Example: genital size increase with hormones of puberty Pathologic hypertrophy - disease process Example - Left ventricular hypertrophy from hypertension -> congestive heart failure Triggers for hypertrophy Mechanical: stretch, exercise Trophic: growth factors, hormones, vasoactive agents CELLULAR HYPERTROPY Left: dependent edema in CHF Right: dilated cardiomyopathy Left ventricular hypertrophy (bottom) vs normal (top) © 2004 Lois E. Brenneman, MSN, CS, ANP, FNP all rights reserved - www.npceu.com 2 Hyperplasia - increase in number of cells (increased rate of cell division) - Can occur in response to injury esp with cell death - Can occur together with hypertrophy note: if organ with non-dividing cells (e.g.
    [Show full text]
  • Chapter 1 Cellular Reaction to Injury 3
    Schneider_CH01-001-016.qxd 5/1/08 10:52 AM Page 1 chapter Cellular Reaction 1 to Injury I. ADAPTATION TO ENVIRONMENTAL STRESS A. Hypertrophy 1. Hypertrophy is an increase in the size of an organ or tissue due to an increase in the size of cells. 2. Other characteristics include an increase in protein synthesis and an increase in the size or number of intracellular organelles. 3. A cellular adaptation to increased workload results in hypertrophy, as exemplified by the increase in skeletal muscle mass associated with exercise and the enlargement of the left ventricle in hypertensive heart disease. B. Hyperplasia 1. Hyperplasia is an increase in the size of an organ or tissue caused by an increase in the number of cells. 2. It is exemplified by glandular proliferation in the breast during pregnancy. 3. In some cases, hyperplasia occurs together with hypertrophy. During pregnancy, uterine enlargement is caused by both hypertrophy and hyperplasia of the smooth muscle cells in the uterus. C. Aplasia 1. Aplasia is a failure of cell production. 2. During fetal development, aplasia results in agenesis, or absence of an organ due to failure of production. 3. Later in life, it can be caused by permanent loss of precursor cells in proliferative tissues, such as the bone marrow. D. Hypoplasia 1. Hypoplasia is a decrease in cell production that is less extreme than in aplasia. 2. It is seen in the partial lack of growth and maturation of gonadal structures in Turner syndrome and Klinefelter syndrome. E. Atrophy 1. Atrophy is a decrease in the size of an organ or tissue and results from a decrease in the mass of preexisting cells (Figure 1-1).
    [Show full text]